文献速递淋巴瘤

结外NK/T细胞淋巴瘤患者中枢神经系统复发的预测与预防

Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
PubMed 文献 · Blood · 2020-01-01

研究基于训练队列399例和验证队列253例接受非蒽环类化疗的结外NK/T细胞淋巴瘤患者,开发了中枢神经系统预后指数(CNS-PINK)模型,并评估含中剂量甲氨蝶呤方案预防中枢神经系统复发的必要性。CNS-PINK高危组中枢神经系统复发累积发病率在训练队列(P<.001)和验证队列(P<.038)中均不同,训练队列中高危组接受含中剂量甲氨蝶呤的SMILE或SMILE样方案者复发率低于未接受者(P=.029)。作者认为CNS-PINK对中枢神经系统复发有较强预测能力,S-ID-MTX的预防效果需未来研究验证。

要点

  • CNS-PINK模型由PINK(HR 2.908,P=.030)和结外受累≥2处(HR 4.161,P=.001)各1分构成,2分为高危组。
  • 训练队列中CNS-PINK高危组接受S-ID-MTX方案者中枢神经系统复发率低于未接受中剂量甲氨蝶呤者(P=.029)。
  • CNS-PINK高危组中枢神经系统复发累积发病率在训练队列(P<.001)和验证队列(P=.038)中均不同。

核心结论

  • CNS-PINK对结外NK/T细胞淋巴瘤患者中枢神经系统复发显示出较强预测能力。
  • S-ID-MTX在高危CNS-PINK患者中预防中枢神经系统事件的有效性需未来研究验证。

研究设计与样本

  • 回顾性分析训练队列399例和验证队列253例接受非蒽环类化疗的结外NK/T细胞淋巴瘤患者记录。
  • 根据化疗方案是否包含中剂量甲氨蝶呤(>2 g/m2)将患者分为2组。
  • 使用PINK(HR 2.908,P=.030)和结外受累≥2处(HR 4.161,P=.001)各1分构建CNS-PINK模型,2分为高危组。

主要发现

  • CNS-PINK高危组中枢神经系统复发累积发病率在训练队列中不同(P<.001),在验证队列中不同(P=.038)。
  • 训练队列中CNS-PINK高危组接受S-ID-MTX方案者中枢神经系统复发率低于未接受中剂量甲氨蝶呤的其他方案者(P=.029)。

关键数值与推荐

  • CNS-PINK评分:PINK 1分(HR 2.908,P=.030),结外受累≥2处1分(HR 4.161,P=.001),总分2分为高危组。
  • 中剂量甲氨蝶呤定义为>2 g/m2。

局限性

  • S-ID-MTX在高危CNS-PINK患者中预防中枢神经系统事件的有效性需未来研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Because non-anthracycline-based chemotherapy with l-asparaginase has improved survival outcomes in patients with extranodal natural killer/T-cell lymphoma (ENKTL), the incidence of central nerve system (CNS) relapse can be different when compared with that in previous reports. In this research, we sought to identify the incidence of and predictors for CNS relapse and to evaluate the necessity of CNS prophylaxis with intermediate-dose methotrexate (ID-MTX). The records of 399 patients in the training cohort and 253 patients in the validation cohort with ENKTL who received non-anthracycline-based chemotherapy were reviewed. Patients were divided into 2 groups according to whether the chemotherapy regimen included ID-MTX above 2 g/m2. A new central nervous system-prognostic index of natural killer (CNS-PINK) model was developed using 1-point powerful predictors of CNS relapse (PINK; hazard ratio [HR], 2.908; P = .030 and extranodal involvement [≥2]; HR, 4.161; P = .001) and was calculated as a sum of scores. The high-risk group of CNS-PINK was defined as 2 points. The cumulative incidence of CNS relapse was different between the CNS-PINK risk groups in the training (P < .001) and validation (P = .038) cohorts. Patients in the high-risk CNS-PINK group who were treated with SMILE or SMILE-like regimens with ID-MTX (S-ID-MTX) displayed a lower incidence rate of CNS relapse than did those who received other regimens without ID-MTX in the training cohort (P = .029). The CNS-PINK was demonstrated its strong predictability of CNS relapse in ENKTL patients. The effectiveness of S-ID-MTX in preventing CNS events in high-risk CNS-PINK patients should be verified in future studies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kim H, Jeong H, Yamaguchi M, et al. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood. 2020. PMID: 32584959. doi:10.1182/blood.2020005026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。